Gilead Sciences (GILD)
Market Price (8/20/2026): $146.0 | Market Cap: $181.5 BilInvestor Relations Sector: Health Care | Industry: Biotechnology
Gilead Sciences (GILD)
Market Price (8/20/2026): $146.0Market Cap: $181.5 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 38% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 44%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 42%, CFO LTM is 14 Bil, FCF LTM is 13 Bil Attractive yieldDividend Yield is 2.2%, FCF Yield is 7.1% Stock buyback supportStock Buyback 3Y Total is 4.3 Bil Low stock price volatilityVol 12M is 26% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. | Trading close to highsDist 52W High is -4.1%, Dist 3Y High is -4.1% | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.9% Key risksGILD key risks include [1] looming patent expirations and subsequent generic competition for its highly profitable HIV franchise and [2] pipeline setbacks, Show more. |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 38% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 44%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 42%, CFO LTM is 14 Bil, FCF LTM is 13 Bil |
| Attractive yieldDividend Yield is 2.2%, FCF Yield is 7.1% |
| Stock buyback supportStock Buyback 3Y Total is 4.3 Bil |
| Low stock price volatilityVol 12M is 26% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. |
| Trading close to highsDist 52W High is -4.1%, Dist 3Y High is -4.1% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.9% |
| Key risksGILD key risks include [1] looming patent expirations and subsequent generic competition for its highly profitable HIV franchise and [2] pipeline setbacks, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 8/18/2026
Gilead Sciences (GILD) stock has gained about 15% since 4/30/2026 because of the following key factors:
1. Strong Fiscal Q2 2026 Financial Performance Exceeding Expectations.
Gilead Sciences reported robust financial results for fiscal Q2 2026 (which ended June 30, 2026), with total revenues increasing 10% year-over-year to $7.8 billion, surpassing analyst consensus estimates of $7.35 billion to $7.4 billion. The company also reported a non-GAAP diluted loss of $(6.75) per share, which was narrower than analysts' anticipated loss of $(7.25) to $(7.14) by $0.50. This strong performance was primarily driven by solid sales in its core HIV franchise, with product sales (excluding Veklury) rising 10% year-over-year, and Biktarvy sales alone growing 7% to $3.8 billion in fiscal Q2 2026.
2. Critical Legal Victories Protecting the Flagship HIV Franchise.
Gilead Sciences received a significant boost from two favorable legal rulings in August 2026 that protect its vital HIV revenue streams. A federal appeals court upheld a preliminary injunction on August 13, blocking several companies from importing and selling cheaper foreign versions of Gilead's leading HIV drug, Biktarvy, in the U.S. This ruling helps safeguard Biktarvy, which generated approximately $14.3 billion in full-year 2025 sales and $3.8 billion in fiscal Q2 2026. Additionally, on August 3, the California Supreme Court ruled in Gilead's favor in a separate "duty to innovate" case, dismissing claims related to older HIV drugs.
Show more
Gilead Sciences (GILD) stock has gained about 15% since 4/30/2026 because of the following key factors:
1. Strong Fiscal Q2 2026 Financial Performance Exceeding Expectations.
Gilead Sciences reported robust financial results for fiscal Q2 2026 (which ended June 30, 2026), with total revenues increasing 10% year-over-year to $7.8 billion, surpassing analyst consensus estimates of $7.35 billion to $7.4 billion. The company also reported a non-GAAP diluted loss of $(6.75) per share, which was narrower than analysts' anticipated loss of $(7.25) to $(7.14) by $0.50. This strong performance was primarily driven by solid sales in its core HIV franchise, with product sales (excluding Veklury) rising 10% year-over-year, and Biktarvy sales alone growing 7% to $3.8 billion in fiscal Q2 2026.
2. Critical Legal Victories Protecting the Flagship HIV Franchise.
Gilead Sciences received a significant boost from two favorable legal rulings in August 2026 that protect its vital HIV revenue streams. A federal appeals court upheld a preliminary injunction on August 13, blocking several companies from importing and selling cheaper foreign versions of Gilead's leading HIV drug, Biktarvy, in the U.S. This ruling helps safeguard Biktarvy, which generated approximately $14.3 billion in full-year 2025 sales and $3.8 billion in fiscal Q2 2026. Additionally, on August 3, the California Supreme Court ruled in Gilead's favor in a separate "duty to innovate" case, dismissing claims related to older HIV drugs.
Show more
Updated on 8/18/2026
Gilead Sciences (GILD) stock has gained about 15% since 4/30/2026 because of the following key factors:
1. Strong Fiscal Q2 2026 Financial Performance Exceeding Expectations.
Gilead Sciences reported robust financial results for fiscal Q2 2026 (which ended June 30, 2026), with total revenues increasing 10% year-over-year to $7.8 billion, surpassing analyst consensus estimates of $7.35 billion to $7.4 billion. The company also reported a non-GAAP diluted loss of $(6.75) per share, which was narrower than analysts' anticipated loss of $(7.25) to $(7.14) by $0.50. This strong performance was primarily driven by solid sales in its core HIV franchise, with product sales (excluding Veklury) rising 10% year-over-year, and Biktarvy sales alone growing 7% to $3.8 billion in fiscal Q2 2026.
2. Critical Legal Victories Protecting the Flagship HIV Franchise.
Gilead Sciences received a significant boost from two favorable legal rulings in August 2026 that protect its vital HIV revenue streams. A federal appeals court upheld a preliminary injunction on August 13, blocking several companies from importing and selling cheaper foreign versions of Gilead's leading HIV drug, Biktarvy, in the U.S. This ruling helps safeguard Biktarvy, which generated approximately $14.3 billion in full-year 2025 sales and $3.8 billion in fiscal Q2 2026. Additionally, on August 3, the California Supreme Court ruled in Gilead's favor in a separate "duty to innovate" case, dismissing claims related to older HIV drugs.
3. Positive Pipeline Progress and Regulatory Approvals in Key Therapeutic Areas.
The company demonstrated continued momentum in its pipeline, securing three FDA approvals and reporting three positive Phase 3 clinical trial updates during fiscal Q2 2026. Key regulatory milestones included the U.S. FDA approval of Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer in June 2026, and the accelerated FDA approval of Hepcludex on May 22, 2026, for chronic hepatitis delta virus infection. Furthermore, positive Phase 3 results for an investigational once-weekly oral HIV treatment regimen of Islatravir/Lenacapavir were presented in July 2026, which will support future regulatory submissions.
4. Favorable Analyst Sentiment and Strategic Portfolio Expansion.
Analyst sentiment for Gilead Sciences remained largely positive during the period, with a "Moderate Buy" consensus rating from analysts and an average price target of $158.04, indicating potential upside for the stock. Complementing this, Gilead completed strategic acquisitions of Tubulis and Ouro Medicines in fiscal Q2 2026. These acquisitions expanded the company's oncology and inflammation pipelines, signaling a commitment to diversifying its product portfolio beyond its established HIV business.
Show less
Gilead Sciences (GILD) stock has gained about 15% since 4/30/2026 because of the following key factors:
1. Strong Fiscal Q2 2026 Financial Performance Exceeding Expectations.
Gilead Sciences reported robust financial results for fiscal Q2 2026 (which ended June 30, 2026), with total revenues increasing 10% year-over-year to $7.8 billion, surpassing analyst consensus estimates of $7.35 billion to $7.4 billion. The company also reported a non-GAAP diluted loss of $(6.75) per share, which was narrower than analysts' anticipated loss of $(7.25) to $(7.14) by $0.50. This strong performance was primarily driven by solid sales in its core HIV franchise, with product sales (excluding Veklury) rising 10% year-over-year, and Biktarvy sales alone growing 7% to $3.8 billion in fiscal Q2 2026.
2. Critical Legal Victories Protecting the Flagship HIV Franchise.
Gilead Sciences received a significant boost from two favorable legal rulings in August 2026 that protect its vital HIV revenue streams. A federal appeals court upheld a preliminary injunction on August 13, blocking several companies from importing and selling cheaper foreign versions of Gilead's leading HIV drug, Biktarvy, in the U.S. This ruling helps safeguard Biktarvy, which generated approximately $14.3 billion in full-year 2025 sales and $3.8 billion in fiscal Q2 2026. Additionally, on August 3, the California Supreme Court ruled in Gilead's favor in a separate "duty to innovate" case, dismissing claims related to older HIV drugs.
3. Positive Pipeline Progress and Regulatory Approvals in Key Therapeutic Areas.
The company demonstrated continued momentum in its pipeline, securing three FDA approvals and reporting three positive Phase 3 clinical trial updates during fiscal Q2 2026. Key regulatory milestones included the U.S. FDA approval of Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer in June 2026, and the accelerated FDA approval of Hepcludex on May 22, 2026, for chronic hepatitis delta virus infection. Furthermore, positive Phase 3 results for an investigational once-weekly oral HIV treatment regimen of Islatravir/Lenacapavir were presented in July 2026, which will support future regulatory submissions.
4. Favorable Analyst Sentiment and Strategic Portfolio Expansion.
Analyst sentiment for Gilead Sciences remained largely positive during the period, with a "Moderate Buy" consensus rating from analysts and an average price target of $158.04, indicating potential upside for the stock. Complementing this, Gilead completed strategic acquisitions of Tubulis and Ouro Medicines in fiscal Q2 2026. These acquisitions expanded the company's oncology and inflammation pipelines, signaling a commitment to diversifying its product portfolio beyond its established HIV business.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 13.6% change in GILD stock from 4/30/2026 to 8/19/2026 was primarily driven by a 9.9% change in the company's P/S Multiple.| (LTM values as of) | 4302026 | 8192026 | Change |
|---|---|---|---|
| Stock Price ($) | 129.99 | 147.60 | 13.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 29,441 | 30,456 | 3.4% |
| P/S Multiple | 5.5 | 6.0 | 9.9% |
| Shares Outstanding (Mil) | 1,241 | 1,243 | -0.2% |
| Cumulative Contribution | 13.6% |
Market Drivers
4/30/2026 to 8/19/2026| Return | Correlation | |
|---|---|---|
| GILD | 13.6% | |
| Market (SPY) | 7.0% | 3.6% |
| Sector (XLV) | 20.3% | 56.7% |
Fundamental Drivers
The 5.3% change in GILD stock from 1/31/2026 to 8/19/2026 was primarily driven by a 4.7% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 8192026 | Change |
|---|---|---|---|
| Stock Price ($) | 140.23 | 147.60 | 5.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 29,086 | 30,456 | 4.7% |
| P/S Multiple | 6.0 | 6.0 | 0.5% |
| Shares Outstanding (Mil) | 1,243 | 1,243 | 0.0% |
| Cumulative Contribution | 5.3% |
Market Drivers
1/31/2026 to 8/19/2026| Return | Correlation | |
|---|---|---|
| GILD | 5.3% | |
| Market (SPY) | 11.4% | 17.9% |
| Sector (XLV) | 14.0% | 59.1% |
Fundamental Drivers
The 34.9% change in GILD stock from 7/31/2025 to 8/19/2026 was primarily driven by a 26.9% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 8192026 | Change |
|---|---|---|---|
| Stock Price ($) | 109.44 | 147.60 | 34.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 28,734 | 30,456 | 6.0% |
| P/S Multiple | 4.7 | 6.0 | 26.9% |
| Shares Outstanding (Mil) | 1,246 | 1,243 | 0.2% |
| Cumulative Contribution | 34.9% |
Market Drivers
7/31/2025 to 8/19/2026| Return | Correlation | |
|---|---|---|
| GILD | 34.9% | |
| Market (SPY) | 22.7% | 15.3% |
| Sector (XLV) | 36.4% | 50.5% |
Fundamental Drivers
The 114.0% change in GILD stock from 7/31/2023 to 8/19/2026 was primarily driven by a 89.2% change in the company's P/S Multiple.| (LTM values as of) | 7312023 | 8192026 | Change |
|---|---|---|---|
| Stock Price ($) | 68.99 | 147.60 | 114.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 27,043 | 30,456 | 12.6% |
| P/S Multiple | 3.2 | 6.0 | 89.2% |
| Shares Outstanding (Mil) | 1,248 | 1,243 | 0.4% |
| Cumulative Contribution | 114.0% |
Market Drivers
7/31/2023 to 8/19/2026| Return | Correlation | |
|---|---|---|
| GILD | 114.0% | |
| Market (SPY) | 73.9% | 20.3% |
| Sector (XLV) | 37.1% | 48.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| GILD Return | 30% | 24% | -2% | 19% | 37% | 18% | 202% |
| Peers Return | 23% | 18% | -15% | 4% | 18% | 24% | 88% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 105% |
Monthly Win Rates [3] | |||||||
| GILD Win Rate | 58% | 33% | 42% | 67% | 67% | 62% | |
| Peers Win Rate | 58% | 62% | 37% | 48% | 60% | 68% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| GILD Max Drawdown | -10% | -20% | -14% | -27% | -17% | -22% | |
| Peers Max Drawdown | -17% | -18% | -26% | -21% | -22% | -13% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ABBV, MRK, BMY, PFE, JNJ. See GILD Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/19/2026 (YTD)
How Low Can It Go
| Event | GILD | S&P 500 |
|---|---|---|
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -13.3% | -6.7% |
| % Gain to Breakeven | 15.3% | 7.1% |
| Time to Breakeven | 181 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -20.2% | -24.5% |
| % Gain to Breakeven | 25.3% | 32.4% |
| Time to Breakeven | 230 days | 427 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -22.7% | -19.2% |
| % Gain to Breakeven | 29.4% | 23.8% |
| Time to Breakeven | 436 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -17.7% | -3.7% |
| % Gain to Breakeven | 21.4% | 3.9% |
| Time to Breakeven | 83 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -28.4% | -12.2% |
| % Gain to Breakeven | 39.6% | 13.9% |
| Time to Breakeven | 2908 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -22.2% | -6.8% |
| % Gain to Breakeven | 28.5% | 7.3% |
| Time to Breakeven | 2484 days | 15 days |
In The Past
Gilead Sciences's stock fell -9.3% during the 2025 US Tariff Shock. Such a loss loss requires a 10.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | GILD | S&P 500 |
|---|---|---|
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -20.2% | -24.5% |
| % Gain to Breakeven | 25.3% | 32.4% |
| Time to Breakeven | 230 days | 427 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -22.7% | -19.2% |
| % Gain to Breakeven | 29.4% | 23.8% |
| Time to Breakeven | 436 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -28.4% | -12.2% |
| % Gain to Breakeven | 39.6% | 13.9% |
| Time to Breakeven | 2908 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -22.2% | -6.8% |
| % Gain to Breakeven | 28.5% | 7.3% |
| Time to Breakeven | 2484 days | 15 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -21.3% | -15.4% |
| % Gain to Breakeven | 27.0% | 18.2% |
| Time to Breakeven | 231 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -20.5% | -53.4% |
| % Gain to Breakeven | 25.8% | 114.4% |
| Time to Breakeven | 24 days | 1085 days |
In The Past
Gilead Sciences's stock fell -9.3% during the 2025 US Tariff Shock. Such a loss loss requires a 10.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Gilead Sciences (GILD)
Gilead Sciences, Inc. (GILD) is a global biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for areas of unmet medical need across the United States, Europe, and other international markets. The company's core mission involves creating life-saving and life-improving treatments for a range of serious illnesses, working at the forefront of medical science to address complex health challenges.
Gilead's extensive product portfolio targets several critical disease areas. It is a recognized leader in HIV/AIDS treatment, with key products including Biktarvy and Genvoya, and also developed Veklury for COVID-19. Additionally, the company offers significant therapies for liver diseases such as Epclusa and Harvoni. Expanding its reach, Gilead has a growing presence in hematology, oncology, and cell therapy with products like Yescarta and Trodelvy for various cancers. Its primary customers are patients and healthcare providers globally, who rely on these specialized medicines to manage and treat complex and life-threatening conditions.
AI Analysis | Feedback
The Pfizer or Merck of antiviral and oncology treatments.
Like a Bristol Myers Squibb, but historically a leader in breakthrough antiviral and liver disease medicines.
AI Analysis | Feedback
- Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Atripla: Products for the treatment of HIV/AIDS.
- Veklury: An injection for intravenous use for the treatment of coronavirus disease 2019 (COVID-19).
- Epclusa, Harvoni, Vosevi, Vemlidy, Viread: Products for the treatment of liver diseases.
- Yescarta, Tecartus, Trodelvy, Zydelig: Products for the treatment of hematology, oncology, and cell therapy patients.
- Letairis: An oral formulation for the treatment of pulmonary arterial hypertension.
- Ranexa: An oral formulation for the treatment of chronic angina.
- AmBisome: A liposomal formulation for the treatment of serious invasive fungal infections.
AI Analysis | Feedback
```html
Gilead Sciences, Inc. (GILD) primarily sells its pharmaceutical products to major wholesale distributors, who then distribute them to pharmacies, hospitals, and other healthcare providers. The company's major customers are:
```AI Analysis | Feedback
null
AI Analysis | Feedback
```html
Daniel P. O'Day, Chairman and Chief Executive Officer
Daniel P. O'Day joined Gilead Sciences in March 2019 as Chairman and Chief Executive Officer. Before his tenure at Gilead, he served as the Chief Executive Officer of Roche Pharmaceuticals for over three decades, where he held various executive positions across the company’s pharmaceutical and diagnostics divisions in North America, Europe, and Asia. He was also a member of Roche's Corporate Executive Committee and served on the boards of Genentech, Flatiron Health, and Foundation Medicine. Mr. O'Day holds a bachelor's degree in biology from Georgetown University and an MBA from Columbia University.
Andrew Dickinson, Chief Financial Officer
Andrew Dickinson was appointed Chief Financial Officer of Gilead Sciences, effective November 1, 2019, having joined the company in 2016. In this role, he is responsible for the company's global finance, corporate development, information technology, operations, and strategy organizations. Prior to joining Gilead, Mr. Dickinson was the Global Co-Head of Healthcare Investment Banking at Lazard Frères & Co. for nine years. Earlier in his career, he served as General Counsel and Vice President of Corporate Development at Myogen, Inc., which was acquired by Gilead in 2006. He earned a B.A. in molecular, cellular, and developmental biology from the University of Colorado at Boulder and a J.D. from Loyola University of Chicago.
Johanna Mercier, Chief Commercial & Corporate Affairs Officer
Johanna Mercier joined Gilead in 2019 as Chief Commercial & Corporate Affairs Officer, with responsibility for driving global commercialization and expanding access to Gilead's therapies. Prior to Gilead, she spent 25 years at Bristol-Myers Squibb, where she held various senior leadership roles across the U.S. and international markets, including President and Head of BMS' Large Markets division. Ms. Mercier holds a bachelor's degree in biology from the University of Montreal and an MBA from Concordia University.
Flavius Martin, MD, Executive Vice President, Research
Flavius Martin, MD, joined Gilead as Executive Vice President, Research, in April 2021, overseeing the company's innovative research and preclinical programs. Before coming to Gilead, he was Vice President, Research Biology at Amgen, where he led Oncology, Inflammation, and Cardiometabolic Research and was the site head for Amgen South San Francisco. He also worked as a scientist and leader at Genentech prior to Amgen. Dr. Martin received his MD degree from the University of Medicine and Pharmacy Timisoara, Romania, and completed his postdoctoral studies at the University of Alabama at Birmingham.
Dietmar Berger, MD, PhD, Chief Medical Officer
Dietmar Berger, MD, PhD, joined Gilead Sciences as Chief Medical Officer on January 2, 2025. In this role, he is responsible for the company’s virology, oncology, and inflammation pipeline, as well as its global Development and Medical Affairs organizations. Dr. Berger is a board-certified internist, hematologist, and oncologist with over 25 years of experience in developing and delivering innovative medicines. Before joining Gilead, he served as Senior Vice President, Chief Medical Officer, and Global Head of Development at Sanofi. His prior experience also includes executive and development roles at Atara Biotherapeutics Inc., Genentech Inc., Bayer Healthcare Pharmaceuticals Inc., and Amgen Inc. He is a Professor of Medicine at the University of Freiburg Hospital in Germany and holds an MD and PhD from the Albert-Ludwigs University School of Medicine.
AI Analysis | Feedback
The public company Gilead Sciences (symbol: GILD) faces several key risks to its business operations and future growth.
- Intensifying Competition and Market Share Erosion: Gilead operates in highly competitive therapeutic areas, particularly in HIV and oncology, where it faces significant rivalry from other major biopharmaceutical companies such as ViiV Healthcare, Roche, Bristol Myers Squibb (BMS), Novartis, Pfizer, and Amgen. This competition can lead to market share losses, pricing pressures, and the need for continuous innovation to maintain its market position. Furthermore, the expiration of patents on key drugs can lead to the entry of generic and biosimilar versions, causing substantial revenue declines and impacting profitability. While its major HIV drug, Biktarvy, has primary patent protection until 2027 and other patents extending to 2033, the company has experienced revenue losses and workforce reductions due to patent expirations on other products like Ranexa and Letairis. Gilead has also faced antitrust lawsuits alleging anticompetitive practices aimed at delaying the entry of generic competitors for its HIV treatments, which could result in significant legal and financial consequences.
- Pipeline Dependence and Clinical Trial Setbacks: As a biopharmaceutical company, Gilead's future growth is heavily dependent on the successful development and commercialization of new medicines from its pipeline. There are inherent risks associated with clinical trials, including the potential for unfavorable results, delays in timelines, or even outright failures. For example, the FDA has placed clinical holds on some of Gilead's investigational HIV programs. A notable setback was the abandonment of its anti-CD47 drug magrolimab, which was found to be ineffective and potentially harmful in a Phase 3 study, highlighting the significant financial and strategic risks associated with pipeline failures. Additionally, the company faces "pipeline liability" lawsuits alleging that it delayed bringing safer alternative drugs to market, which could create new legal precedents and financial liabilities.
- Regulatory and Legal Scrutiny: Beyond antitrust-related litigation, Gilead is subject to extensive regulatory and legal oversight that can significantly impact its business. This includes the risk of increased government regulation on drug pricing in the United States and Europe, which could pressure operating margins. The company has also faced scrutiny from the SEC regarding oncology revenue reporting and is subject to class-action lawsuits, which introduce financial uncertainties, potential fines, and reputational damage. Regulatory actions, such as FDA clinical holds on development programs, can cause significant delays and impact the trajectory of key pipeline assets.
AI Analysis | Feedback
null
AI Analysis | Feedback
Here are the addressable market sizes for Gilead Sciences' main products and services:
- HIV Drugs: The global HIV drugs market size was valued at USD 32.85 billion in 2024 and is estimated to reach USD 45.07 billion by 2033. Another source indicates the global HIV drugs market size was USD 38.27 billion in 2025 and is projected to grow to USD 66.09 billion by 2034. The market was valued at USD 32,804.43 million in 2022 and is estimated to reach USD 51,046.10 million by 2032. North America is the leading region in this market.
- COVID-19 Antiviral Treatments (Veklury): The specific antiviral drugs for COVID-19 market size was USD 15.23 billion in 2025 and is projected to reach USD 33.17 billion in 2030. The global COVID-19 therapeutics market size was USD 32542.5 million in 2025. The global COVID-19 infection market size was valued at USD 26.82 billion in 2024 and is expected to reach USD 70.31 billion by 2032.
- Hepatitis C (Epclusa, Harvoni, Vosevi): The global hepatitis C testing market size was valued at $1.5 billion in 2023 and is projected to reach $2.6 billion by 2035. The hepatitis C market size reached a value of USD 18.0 billion in 2023 and is expected to reach USD 47.1 billion by 2034. Another report states the global hepatitis C market size was USD 7.95 billion in 2024 and is anticipated to reach around USD 10.62 billion by 2034. The hepatitis C market size was USD 75.72 billion in 2025 and is expected to grow to USD 153.67 billion in 2030.
- Hepatitis B (Vemlidy, Viread): The global hepatitis B vaccine market was valued at USD 6.7 billion in 2024 and is expected to grow to USD 12 billion by 2034. The hepatitis B therapeutics market size is forecast to increase by USD 469.5 million between 2023 and 2028. The global hepatitis B market is accounted at USD 4.94 billion in 2025 and is predicted to increase to approximately USD 6.86 billion by 2035. Another source indicates the global hepatitis B therapeutics market size was USD 2.48 billion in 2025 and is projected to grow to USD 6.66 billion in 2034.
- CAR T-cell Therapy (Yescarta, Tecartus): The global CAR T-cell therapy market size was estimated at USD 5.82 billion in 2025 and is projected to reach USD 22.36 billion by 2033. Other estimates include USD 8.95 billion in 2025, projected to USD 19.25 billion by 2034, and USD 20.54 billion in 2025, projected to surpass USD 268.0 billion by 2035. North America dominated the global CAR T-cell therapy market.
- Trodelvy (Oncology): Global sales for Trodelvy are expected to reach nearly $3 billion by 2029.
- Pulmonary Arterial Hypertension (Letairis): The global pulmonary arterial hypertension market size was estimated at USD 8.02 billion in 2024 and is projected to reach USD 13.34 billion by 2033. Other estimates include USD 8.11 billion in 2025, estimated to reach USD 11.27 billion by 2031, and USD 8.48 billion in 2025, predicted to increase to approximately USD 13.50 billion by 2034. North America maintains the largest share of this market.
- Chronic Angina (Ranexa): The angina market size was $10.71 billion in 2024 and is expected to grow to $14.44 billion in 2029. Another source indicates the global angina market is expected to reach $14.84 billion by 2030. The global angina pectoris drugs market size was estimated at USD 11.37 billion in 2023 and is projected to reach USD 15.71 billion by 2030. North America was the largest region in the angina market in 2024.
- Invasive Fungal Infections (AmBisome): The Invasive Fungal Infection Market was valued at USD 7.55 billion in 2024, and is expected to reach USD 9.44 billion by 2030. Another source states the global invasive fungal infection market was valued at USD 6.61 billion in 2022 and is expected to reach USD 9.06 billion in 2030. The invasive fungal infections market size is expected to grow to $10.1 billion in 2030. North America holds the largest market share in the global invasive fungal infection market.
AI Analysis | Feedback
Gilead Sciences (NASDAQ: GILD) is anticipated to drive future revenue growth over the next 2-3 years through several key strategies and product advancements:
- Continued Growth in the HIV Franchise: Gilead expects sustained growth from its leading HIV treatments, such as Biktarvy and Descovy. Additionally, the company is seeing significant momentum and growth in its HIV prevention business, particularly with new long-acting therapies like Yeztugo, a twice-yearly injectable, which has exceeded coverage goals and is gaining market share. This HIV prevention market is expected to continue developing and growing for many years.
- Expansion of the Oncology Portfolio: Diversification into oncology is a key driver, with products like Trodelvy showing positive sales momentum and contributing to revenue growth. The acquisition of Arcellx and the potential of anito-cel in the multiple myeloma market are also expected to bolster Gilead's oncology footprint and future revenues. Gilead reported approximately $3 billion in oncology revenues in 2025, accounting for about 12% of total revenues, with a sales target of $800 million for Yeztugo in 2026.
- Growth in the Liver Disease Segment: The company's liver disease business, driven by therapies such as Livdelzi for primary biliary cholangitis, has shown strong performance. Livdelzi, in particular, has seen a positive start to its launch and is projected to exceed $1 billion in peak revenue.
- Robust Pipeline and New Product Launches: Gilead boasts a strong pipeline with plans for up to 10 ongoing and potential new launches through 2027, including four commercial launches planned for 2026. A significant portion of these new products (6 out of 8 planned launches) are outside of its core HIV business, signaling a strategic diversification that is expected to broaden the company's revenue base and drive growth across varied therapeutic areas.
AI Analysis | Feedback
Share Repurchases
- Gilead's annual share buybacks totaled $1.922 billion in 2025.
- The company repurchased $1.15 billion in shares during 2024.
- Share repurchases amounted to $1 billion in 2023.
Outbound Investments
- Gilead announced the acquisition of Arcellx for approximately $8 billion in early 2026 to enhance its cell therapy portfolio, focusing on anito-cel for multiple myeloma.
- In March 2024, Gilead acquired CymaBay Therapeutics Inc. for $4.3 billion, integrating Seladelpar into its liver disease portfolio.
- The company anticipated the acquisition of Interius BioTherapeutics for $350 million in cash, with the transaction expected in the fourth quarter of 2025.
Capital Expenditures
- Gilead announced an additional $11 billion investment in its U.S. operations through 2030, bringing its total U.S. manufacturing and R&D investments to over $32 billion.
- The $11 billion investment includes $4 billion allocated to capital projects such as labs and equipment, $5 billion for technology, operations, and R&D site activities, and $2 billion for digital and advanced engineering initiatives.
- Annual capital expenditures were estimated at $563 million in 2025, $523 million in 2024, and $585 million in 2023.
Peer Outperformance in Biotechnology
GILD has outperformed 88% of its 365 Biotechnology peers over 5Y. Among the peers that beat it are PTGX and ABBV. Biotechnology ranks 10th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Biotechnology constituents that GILD has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
54%
of 462 industry peers · 28.4% return
3Y
77%
of 407 industry peers · 114.7% return
5Y
88%
of 365 industry peers · 144.5% return
Biotechnology peers with revenue growth within 4pp of GILD's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| GILD | Gilead Sciences | 3.6% | -56.6x | 28.4% | 114.7% | 144.5% | — |
| PTGX | Protagonist Therapeutics | 0.2% | 123.2x | 175.4% | 709.9% | 214.8% | +70pp |
| ABBV | AbbVie | 4.9% | 74.6x | 33.0% | 96.5% | 168.9% | +24pp |
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is GILD's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 8.4% | 80.2% | 137.8% | CAH 410% · MCK 337% · COR 180% |
| Health Care Services | 20 | 19.9% | 44.4% | 9.4% | HIMS 337% · RDNT 147% · DGX 75% |
| Managed Health Care | 8 | 32.1% | -4.0% | -0.3% | OSCR 138% · HQY 65% · ELV 13% |
| Health Care Facilities | 24 | 8.8% | -3.9% | -15.3% | THC 270% · NHC 261% · ENSG 126% |
| Health Care Equipment | 51 | -1.1% | -6.1% | -17.6% | POCI 11000% · UFPT 381% · GKOS 287% |
| Health Care Supplies | 12 | 38.2% | -12.0% | -25.7% | LNTH 302% · HAE 82% · MMSI 33% |
| Pharmaceuticals | 63 | 7.3% | 0.7% | -29.1% | LQDA 2808% · INDV 1373% · ETON 1294% |
| Life Sciences Tools & Services | 108 | -0.5% | -31.3% | -70.9% | SNWV 1990% · ELMD 257% · MEDP 241% |
| Health Care Technology | 20 | -23.4% | -53.0% | -73.9% | SPOK 118% · HSTM -3% · VEEV -22% |
| Biotechnology ← | 366 | 17.1% | -23.9% | -76.7% | BRTX 106550% · DNTH 1652% · CELZ 1500% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 149.90 |
| Mkt Cap | 279.7 |
| Rev LTM | 64,040 |
| Op Inc LTM | 15,430 |
| FCF LTM | 14,503 |
| FCF 3Y Avg | 13,816 |
| CFO LTM | 16,530 |
| CFO 3Y Avg | 16,340 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.1% |
| Rev Chg 3Y Avg | 4.1% |
| Rev Chg Q | 6.2% |
| QoQ Delta Rev Chg LTM | 1.5% |
| Op Inc Chg LTM | 14.5% |
| Op Inc Chg 3Y Avg | 16.7% |
| Op Mgn LTM | 27.5% |
| Op Mgn 3Y Avg | 24.0% |
| QoQ Delta Op Mgn LTM | -0.2% |
| CFO/Rev LTM | 29.1% |
| CFO/Rev 3Y Avg | 29.3% |
| FCF/Rev LTM | 23.7% |
| FCF/Rev 3Y Avg | 25.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 279.7 |
| P/S | 5.8 |
| P/Op Inc | 18.6 |
| P/EBIT | 24.2 |
| P/E | 34.2 |
| P/CFO | 16.2 |
| Total Yield | 4.5% |
| Dividend Yield | 2.4% |
| FCF Yield 3Y Avg | 6.1% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 11.6% |
| 3M Rtn | 18.4% |
| 6M Rtn | 14.2% |
| 12M Rtn | 39.8% |
| 3Y Rtn | 62.9% |
| 1M Excs Rtn | 9.5% |
| 3M Excs Rtn | 13.6% |
| 6M Excs Rtn | 2.2% |
| 12M Excs Rtn | 20.4% |
| 3Y Excs Rtn | -9.0% |
Comparison Analyses
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| BLA761468 | HEPCLUDEX | bulevirtide-gmod | injection | 5222026 | 10.6% | 10.6% | 10.6% | 10.6% | 10.6% |
| NDA220018 | YEZTUGO | lenacapavir | solution | 6182025 | 4.7% | 13.9% | 17.6% | 40.2% | 40.2% |
| NDA220020 | YEZTUGO | lenacapavir sodium | tablet | 6182025 | 4.7% | 13.9% | 17.6% | 40.2% | 40.2% |
| NDA217899 | LIVDELZI | seladelpar lysine | capsule | 8142024 | 26.1% | 41.8% | 65.7% | 97.7% | 110.9% |
| NDA215973 | SUNLENCA | lenacapavir sodium | solution | 12222022 | -6.8% | -6.6% | -3.0% | 17.3% | 94.7% |
| NDA215974 | SUNLENCA | lenacapavir sodium | tablet | 12222022 | -6.8% | -6.6% | -3.0% | 17.3% | 94.7% |
| NDA214187 | EPCLUSA | sofosbuvir | pellets | 6102021 | 3.0% | 3.5% | -8.5% | 22.7% | 158.3% |
| NDA214787 | VEKLURY | remdesivir | solution | 10222020 | 11.7% | 10.7% | 15.7% | 22.2% | 201.8% |
| NDA212480 | SOVALDI | sofosbuvir | pellets | 8282019 | 6.5% | 19.6% | 6.9% | 21.4% | 201.6% |
| NDA212477 | HARVONI | ledipasvir | pellets | 8282019 | 6.5% | 19.6% | 6.9% | 21.4% | 201.6% |
| ... | |||||||||
| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| BLA761468 | HEPCLUDEX | bulevirtide-gmod | injection | 5222026 | 10.6% | 10.6% | 10.6% | 10.6% | 10.6% |
| NDA220018 | YEZTUGO | lenacapavir | solution | 6182025 | 4.7% | 13.9% | 17.6% | 40.2% | 40.2% |
| NDA220020 | YEZTUGO | lenacapavir sodium | tablet | 6182025 | 4.7% | 13.9% | 17.6% | 40.2% | 40.2% |
| NDA217899 | LIVDELZI | seladelpar lysine | capsule | 8142024 | 26.1% | 41.8% | 65.7% | 97.7% | 110.9% |
| NDA215973 | SUNLENCA | lenacapavir sodium | solution | 12222022 | -6.8% | -6.6% | -3.0% | 17.3% | 94.7% |
| NDA215974 | SUNLENCA | lenacapavir sodium | tablet | 12222022 | -6.8% | -6.6% | -3.0% | 17.3% | 94.7% |
| NDA214187 | EPCLUSA | sofosbuvir | pellets | 6102021 | 3.0% | 3.5% | -8.5% | 22.7% | 158.3% |
| NDA214787 | VEKLURY | remdesivir | solution | 10222020 | 11.7% | 10.7% | 15.7% | 22.2% | 201.8% |
| NDA212480 | SOVALDI | sofosbuvir | pellets | 8282019 | 6.5% | 19.6% | 6.9% | 21.4% | 201.6% |
| NDA212477 | HARVONI | ledipasvir | pellets | 8282019 | 6.5% | 19.6% | 6.9% | 21.4% | 201.6% |
| NDA210251 | BIKTARVY | bictegravir sodium | tablet | 2072018 | -20.1% | -5.7% | -16.1% | -10.8% | 143.9% |
| NDA209195 | VOSEVI | sofosbuvir | tablet | 7182017 | 12.6% | 13.4% | 10.6% | -0.1% | 185.2% |
| NDA208464 | VEMLIDY | tenofovir alafenamide fumarate | tablet | 11102016 | -15.2% | -13.1% | -2.5% | -3.1% | 168.6% |
| NDA208341 | EPCLUSA | sofosbuvir | tablet | 6282016 | -3.1% | -9.3% | -10.1% | -9.6% | 155.5% |
| NDA208215 | DESCOVY | emtricitabine | tablet | 4042016 | -9.4% | -16.2% | -27.1% | -15.6% | 124.4% |
| NDA208351 | ODEFSEY | emtricitabine | tablet | 3012016 | -2.5% | -12.2% | -19.9% | -9.0% | 137.0% |
| NDA207561 | GENVOYA | cobicistat | tablet | 11052015 | -19.3% | -19.6% | -31.4% | -28.4% | 97.9% |
| NDA205834 | HARVONI | ledipasvir | tablet | 10102014 | -1.5% | -1.9% | -2.2% | -25.4% | 107.3% |
| NDA203094 | TYBOST | cobicistat | tablet | 9242014 | -16.0% | -8.1% | -5.0% | -23.0% | 97.8% |
| NDA203093 | VITEKTA | elvitegravir | tablet | 9242014 | -16.0% | -8.1% | -5.0% | -23.0% | 97.8% |
| NDA205858 | ZYDELIG | idelalisib | tablet | 7232014 | 17.4% | 14.7% | 30.7% | -2.0% | 138.1% |
| NDA206545 | ZYDELIG | idelalisib | tablet | 7232014 | 17.4% | 14.7% | 30.7% | -2.0% | 138.1% |
| NDA204671 | SOVALDI | sofosbuvir | tablet | 12062013 | 7.6% | 11.4% | 41.4% | 41.7% | 190.7% |
| NDA203100 | STRIBILD | cobicistat | tablet | 8272012 | 32.0% | 47.2% | 105.4% | 275.6% | 652.1% |
| NDA022577 | VIREAD | tenofovir disoproxil fumarate | powder | 1182012 | -1.9% | 11.9% | 63.2% | 230.0% | 805.3% |
| NDA202123 | COMPLERA | emtricitabine | tablet | 8102011 | 12.8% | 53.6% | 61.0% | 235.1% | 1,117.1% |
| NDA050814 | CAYSTON | aztreonam | for solution | 2222010 | -24.1% | -31.4% | -19.6% | -7.0% | 798.3% |
| NDA022081 | LETAIRIS | ambrisentan | tablet | 6152007 | -5.9% | 13.4% | 34.0% | 11.2% | 964.3% |
| NDA021937 | ATRIPLA | efavirenz | tablet | 7122006 | 5.7% | 4.7% | 29.3% | 73.8% | 1,292.2% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Biktarvy | 14,334 | 13,423 | 11,850 | 8,624 | |
| Descovy | 2,758 | 2,113 | 1,985 | 1,700 | |
| Genvoya | 1,498 | 1,762 | 2,060 | 2,879 | |
| Yescarta | 1,495 | 1,570 | 1,498 | 695 | |
| Trodelvy | 1,397 | 1,315 | 1,063 | 380 | |
| Sofosbuvir/Velpatasvir | 1,272 | 1,596 | 1,537 | 1,462 | |
| Odefsey | 1,167 | 1,288 | 1,350 | 1,568 | |
| Vemlidy | 1,070 | 959 | 862 | 814 | |
| Veklury | 911 | 1,799 | 2,184 | 5,565 | |
| Other Liver Disease | 874 | 467 | 385 | ||
| Royalty, contract and other revenues | 527 | 144 | 182 | 297 | |
| AmBisome | 509 | 533 | 492 | 540 | |
| Other Human immunodeficiency virus (HIV) | 500 | 434 | 401 | 195 | |
| Symtuza - Revenue share | 495 | 592 | 529 | 531 | |
| Tecartus | 344 | 403 | 370 | 176 | |
| Other | 290 | 356 | 367 | 281 | |
| Discovery, development and commercialization of innovative medicines in areas of unmet medical need | 27,281 | ||||
| Complera/Eviplera | 258 | ||||
| Ledipasvir/Sofosbuvir | 212 | ||||
| Letairis | 206 | ||||
| Other Hepatitis C virus (HCV) | 207 | ||||
| Other hepatitis B virus (HBV) / hepatitis Delta virus (HDV) | 44 | ||||
| Stribild | 189 | ||||
| Truvada | 371 | ||||
| Viread | 111 | ||||
| Total | 29,441 | 28,754 | 27,115 | 27,281 | 27,305 |
Price Behavior
Price Behavior
| Market Price | $147.60 | |
| Market Cap ($ Bil) | 183.3 | |
| First Trading Date | 01/22/1992 | |
| Distance from 52W High | -4.1% | |
| 50 Days | 200 Days | |
| DMA Price | $130.99 | $131.70 |
| DMA Trend | up | up |
| Distance from DMA | 12.7% | 12.1% |
| 3M | 1YR | |
| Volatility | 30.4% | 26.4% |
| Downside Capture | -74.84 | 1.89 |
| Upside Capture | -3.02 | 30.10 |
| Correlation (SPY) | 1.4% | 15.1% |
GILD Betas & Captures as of 7/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.79 | -0.17 | -0.04 | 0.31 | 0.31 | 0.34 |
| Up Beta | -1.25 | 0.49 | 0.36 | 0.74 | 0.55 | 0.36 |
| Down Beta | 1.36 | 1.00 | 0.85 | 1.05 | 0.43 | 0.41 |
| Up Capture | -102% | -80% | -37% | -10% | 18% | 13% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 9 | 18 | 29 | 60 | 124 | 396 |
| Down Capture | -171% | -80% | -62% | -2% | 13% | 39% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 13 | 25 | 34 | 66 | 127 | 352 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GILD | |
|---|---|---|---|---|
| GILD | 28.5% | 26.3% | 0.92 | - |
| Sector ETF (XLV) | 31.1% | 15.8% | 1.51 | 52.0% |
| Equity (SPY) | 20.7% | 12.8% | 1.19 | 14.9% |
| Gold (GLD) | 35.0% | 28.8% | 1.04 | 9.1% |
| Commodities (DBC) | 41.4% | 20.2% | 1.60 | -11.6% |
| Real Estate (VNQ) | 15.3% | 13.9% | 0.78 | 27.9% |
| Bitcoin (BTCUSD) | -44.7% | 42.7% | -1.27 | 3.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GILD | |
|---|---|---|---|---|
| GILD | 20.5% | 24.6% | 0.73 | - |
| Sector ETF (XLV) | 7.6% | 15.1% | 0.31 | 51.2% |
| Equity (SPY) | 13.1% | 17.2% | 0.59 | 28.4% |
| Gold (GLD) | 20.4% | 18.6% | 0.89 | 4.5% |
| Commodities (DBC) | 9.8% | 19.6% | 0.39 | -1.9% |
| Real Estate (VNQ) | 2.4% | 18.9% | 0.03 | 31.3% |
| Bitcoin (BTCUSD) | 7.2% | 52.6% | 0.32 | 7.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GILD | |
|---|---|---|---|---|
| GILD | 10.2% | 25.5% | 0.40 | - |
| Sector ETF (XLV) | 10.8% | 16.7% | 0.53 | 53.9% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 36.9% |
| Gold (GLD) | 12.5% | 16.2% | 0.63 | 5.2% |
| Commodities (DBC) | 7.9% | 18.1% | 0.35 | 6.7% |
| Real Estate (VNQ) | 4.9% | 20.7% | 0.20 | 28.3% |
| Bitcoin (BTCUSD) | 60.0% | 66.0% | 1.00 | 5.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/13/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/4/2026 | -2.6% | 0.4% | |
| 5/7/2026 | -2.0% | -1.5% | -4.4% |
| 2/10/2026 | 5.8% | 3.7% | -1.4% |
| 10/30/2025 | 1.1% | 4.2% | 4.6% |
| 8/7/2025 | 8.3% | 7.9% | 5.1% |
| 4/24/2025 | -2.8% | -2.7% | 1.1% |
| 2/11/2025 | 7.5% | 12.0% | 17.9% |
| 11/6/2024 | 6.8% | 1.0% | 0.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 14 | 15 |
| # Negative | 13 | 10 | 8 |
| Median Positive | 4.6% | 4.2% | 4.6% |
| Median Negative | -2.6% | -2.2% | -3.8% |
| Max Positive | 12.9% | 13.2% | 21.4% |
| Max Negative | -4.2% | -7.3% | -9.9% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/4/2026 | -2.6% | 0.4% | |
| 5/7/2026 | -2.0% | -1.5% | -4.4% |
| 2/10/2026 | 5.8% | 3.7% | -1.4% |
| 10/30/2025 | 1.1% | 4.2% | 4.6% |
| 8/7/2025 | 8.3% | 7.9% | 5.1% |
| 4/24/2025 | -2.8% | -2.7% | 1.1% |
| 2/11/2025 | 7.5% | 12.0% | 17.9% |
| 11/6/2024 | 6.8% | 1.0% | 0.5% |
| 8/8/2024 | -2.6% | -1.7% | 4.7% |
| 4/25/2024 | 0.2% | 0.1% | 0.6% |
| 2/6/2024 | -4.2% | -5.4% | -5.2% |
| 11/7/2023 | -3.4% | -7.3% | -3.2% |
| 8/3/2023 | 4.2% | 5.9% | 1.5% |
| 4/27/2023 | -1.6% | -6.0% | -7.7% |
| 2/2/2023 | 3.8% | 5.1% | -0.3% |
| 10/27/2022 | 12.9% | 13.2% | 21.4% |
| 8/2/2022 | 4.6% | 4.1% | 6.6% |
| 4/28/2022 | -3.6% | -0.3% | 5.3% |
| 2/1/2022 | -3.9% | -7.0% | -9.9% |
| 10/28/2021 | -3.7% | -1.3% | 4.9% |
| 7/29/2021 | -2.2% | -0.8% | 2.1% |
| 4/29/2021 | -0.6% | 4.2% | 3.6% |
| 2/4/2021 | 4.0% | 1.7% | -1.6% |
| 10/28/2020 | -0.3% | 2.0% | 2.2% |
| SUMMARY STATS | |||
| # Positive | 11 | 14 | 15 |
| # Negative | 13 | 10 | 8 |
| Median Positive | 4.6% | 4.2% | 4.6% |
| Median Negative | -2.6% | -2.2% | -3.8% |
| Max Positive | 12.9% | 13.2% | 21.4% |
| Max Negative | -4.2% | -7.3% | -9.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/23/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/22/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/23/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/22/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/08/2022 | 10-Q |
| 03/31/2022 | 05/04/2022 | 10-Q |
| 12/31/2021 | 02/23/2022 | 10-K |
| 09/30/2021 | 11/03/2021 | 10-Q |
| 06/30/2021 | 08/05/2021 | 10-Q |
| 03/31/2021 | 05/06/2021 | 10-Q |
| 12/31/2020 | 02/25/2021 | 10-K |
| 09/30/2020 | 11/04/2020 | 10-Q |
| 06/30/2020 | 08/06/2020 | 10-Q |
| 03/31/2020 | 05/06/2020 | 10-Q |
| 12/31/2019 | 02/25/2020 | 10-K |
| 09/30/2019 | 11/05/2019 | 10-Q |
Recent Forward Guidance
Updated 8/5/2026Latest: Q2 2026 Earnings Reported 8/4/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Product Sales | 30.10 Bil | 30.25 Bil | 30.40 Bil | 0.2% | Raised | Guidance: 30.20 Bil for 2026 | |
| 2026 Product Sales excluding Veklury | 29.80 Bil | 29.95 Bil | 30.10 Bil | 1.2% | Raised | Guidance: 29.60 Bil for 2026 | |
| 2026 Veklury | 300.00 Mil | -50.0% | Lowered | Guidance: 600.00 Mil for 2026 | |||
| 2026 Diluted loss per share | -3.75 | -3.58 | -3.4 | 17.2% | Lowered | Guidance: -3.05 for 2026 | |
| 2026 Non-GAAP diluted loss per share | -0.65 | -0.47 | -0.3 | -44.1% | Raised | Guidance: -0.85 for 2026 | |
Prior: Q1 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Product sales | 30.00 Bil | 30.20 Bil | 30.40 Bil | 1.3% | Raised | Guidance: 29.80 Bil for 2026 | |
| 2026 Product sales excluding Veklury | 29.40 Bil | 29.60 Bil | 29.80 Bil | 1.4% | Raised | Guidance: 29.20 Bil for 2026 | |
| 2026 Veklury | 600.00 Mil | 0 | Affirmed | Guidance: 600.00 Mil for 2026 | |||
| 2026 Diluted (loss) earnings per share | -3.25 | -3.05 | -2.85 | -143.9% | Lowered | Guidance: 6.95 for 2026 | |
| 2026 Non-GAAP diluted (loss) earnings per share | -1.05 | -0.85 | -0.65 | -109.8% | Lowered | Guidance: 8.65 for 2026 | |
Q4 2025 Earnings Reported 2/10/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Product sales | 29.60 Bil | 29.80 Bil | 30.00 Bil | 4.4% | Higher New | Guidance: 28.55 Bil for 2025 | |
| 2026 Product sales excluding Veklury | 29.00 Bil | 29.20 Bil | 29.40 Bil | 6.0% | Higher New | Guidance: 27.55 Bil for 2025 | |
| 2026 Veklury | 600.00 Mil | -40.0% | Lower New | Guidance: 1.00 Bil for 2025 | |||
| 2026 Diluted EPS | 6.75 | 6.95 | 7.15 | 3.0% | Higher New | Guidance: 6.75 for 2025 | |
| 2026 Non-GAAP diluted EPS | 8.45 | 8.65 | 8.85 | 6.1% | Higher New | Guidance: 8.15 for 2025 | |
Q3 2025 Earnings Reported 10/30/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Product sales | 28.40 Bil | 28.55 Bil | 28.70 Bil | 0.2% | Raised | Guidance: 28.50 Bil for 2025 | |
| 2025 Product sales excluding Veklury | 27.40 Bil | 27.55 Bil | 27.70 Bil | 0.2% | Raised | Guidance: 27.50 Bil for 2025 | |
| 2025 Veklury | 1.00 Bil | 0 | Affirmed | Guidance: 1.00 Bil for 2025 | |||
| 2025 Diluted EPS | 6.65 | 6.75 | 6.85 | 12.5% | Raised | Guidance: 6 for 2025 | |
| 2025 Non-GAAP diluted EPS | 8.05 | 8.15 | 8.25 | 0.6% | Raised | Guidance: 8.1 for 2025 | |
Insider Activity
Updated 8/18/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Mercier, Johanna | Chief Comm & Corp Aff Officer | Direct | Sell | 8182026 | 137.64 | 28,000 | 3,853,908 | 16,273,679 | Form |
| 2 | Dickinson, Andrew D | Chief Financial Officer | Direct | Sell | 8182026 | 138.36 | 3,000 | 415,080 | 22,918,781 | Form |
| 3 | O'Day, Daniel Patrick | Chairman & CEO | Direct | Sell | 8042026 | 130.31 | 15,000 | 1,954,694 | 77,162,570 | Form |
| 4 | Mercier, Johanna | Chief Comm & Corp Aff Officer | Direct | Sell | 7162026 | 129.92 | 3,000 | 389,758 | 15,750,624 | Form |
| 5 | Dickinson, Andrew D | Chief Financial Officer | Direct | Sell | 7162026 | 129.93 | 3,000 | 389,777 | 21,911,433 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Mercier, Johanna | Chief Comm & Corp Aff Officer | Direct | Sell | 8182026 | 137.64 | 28,000 | 3,853,908 | 16,273,679 | Form |
| 2 | Dickinson, Andrew D | Chief Financial Officer | Direct | Sell | 8182026 | 138.36 | 3,000 | 415,080 | 22,918,781 | Form |
| 3 | O'Day, Daniel Patrick | Chairman & CEO | Direct | Sell | 8042026 | 130.31 | 15,000 | 1,954,694 | 77,162,570 | Form |
| 4 | Mercier, Johanna | Chief Comm & Corp Aff Officer | Direct | Sell | 7162026 | 129.92 | 3,000 | 389,758 | 15,750,624 | Form |
| 5 | Dickinson, Andrew D | Chief Financial Officer | Direct | Sell | 7162026 | 129.93 | 3,000 | 389,777 | 21,911,433 | Form |
| 6 | O'Day, Daniel Patrick | Chairman & CEO | Direct | Sell | 7022026 | 126.29 | 15,000 | 1,894,400 | 76,676,848 | Form |
| 7 | Mercier, Johanna | Chief Comm & Corp Aff Officer | Direct | Sell | 6162026 | 123.92 | 3,000 | 371,762 | 15,395,163 | Form |
| 8 | Dickinson, Andrew D | Chief Financial Officer | Direct | Sell | 6162026 | 125.40 | 3,000 | 376,200 | 21,524,408 | Form |
| 9 | O'Day, Daniel Patrick | Chairman & CEO | Direct | Sell | 6022026 | 131.46 | 15,000 | 1,971,847 | 81,183,162 | Form |
| 10 | Mercier, Johanna | Chief Comm & Corp Aff Officer | Direct | Sell | 5182026 | 131.29 | 28,000 | 3,676,199 | 16,513,878 | Form |
| 11 | Dickinson, Andrew D | Chief Financial Officer | Direct | Sell | 5182026 | 132.27 | 3,000 | 396,810 | 22,907,974 | Form |
| 12 | O'Day, Daniel Patrick | Chairman & CEO | Direct | Sell | 4292026 | 129.16 | 10,000 | 1,291,608 | 81,702,883 | Form |
| 13 | Mercier, Johanna | Chief Comm & Corp Aff Officer | Direct | Sell | 4162026 | 140.96 | 3,000 | 422,880 | 18,152,688 | Form |
| 14 | Dickinson, Andrew D | Chief Financial Officer | Direct | Sell | 4162026 | 140.96 | 3,000 | 422,880 | 24,835,883 | Form |
| 15 | O'Day, Daniel Patrick | Chairman & CEO | Direct | Sell | 3302026 | 136.82 | 10,000 | 1,368,162 | 87,913,575 | Form |
| 16 | Mercier, Johanna | Chief Comm & Corp Aff Officer | Direct | Sell | 3172026 | 144.23 | 3,000 | 432,690 | 19,006,485 | Form |
| 17 | Dickinson, Andrew D | Chief Financial Officer | Direct | Sell | 3172026 | 144.23 | 3,000 | 432,690 | 25,844,718 | Form |
| 18 | O'Day, Daniel Patrick | Chairman & CEO | Direct | Sell | 3022026 | 144.79 | 10,000 | 1,447,859 | 92,997,117 | Form |
| 19 | Mercier, Johanna | Chief Comm & Corp Aff Officer | Direct | Sell | 2182026 | 154.44 | 28,000 | 4,324,228 | 18,576,883 | Form |
| 20 | Dickinson, Andrew D | Chief Financial Officer | Direct | Sell | 2182026 | 154.43 | 3,000 | 463,290 | 25,910,111 | Form |
| 21 | O'Day, Daniel Patrick | Chairman & CEO | Direct | Sell | 2062026 | 150.00 | 115,640 | 17,346,000 | 92,086,800 | Form |
| 22 | O'Day, Daniel Patrick | Chairman & CEO | Direct | Sell | 1292026 | 139.89 | 10,000 | 1,398,911 | 77,877,104 | Form |
| 23 | O'Day, Daniel Patrick | Chairman & CEO | Direct | Sell | 1262026 | 135.00 | 115,640 | 15,611,400 | 76,504,230 | Form |
| 24 | Bluestone, Jeffrey | Direct | Sell | 1212026 | 123.50 | 5,000 | 617,500 | 1,101,620 | Form | |
| 25 | Mercier, Johanna | Chief Commercial Officer | Direct | Sell | 1162026 | 124.31 | 3,000 | 372,930 | 12,831,403 | Form |
| 26 | Dickinson, Andrew D | Chief Financial Officer | Direct | Sell | 1162026 | 124.31 | 3,000 | 372,930 | 18,709,028 | Form |
| 27 | O'Day, Daniel Patrick | Chairman & CEO | Direct | Sell | 12302025 | 124.83 | 10,000 | 1,248,272 | 70,739,325 | Form |
| 28 | Dickinson, Andrew D | Chief Financial Officer | Direct | Sell | 12162025 | 122.00 | 3,000 | 366,000 | 18,727,366 | Form |
| 29 | Mercier, Johanna | Chief Commercial Officer | Direct | Sell | 12162025 | 122.00 | 3,000 | 366,000 | 12,958,962 | Form |
| 30 | Bluestone, Jeffrey | Direct | Sell | 12012025 | 125.08 | 5,000 | 625,400 | 1,115,714 | Form | |
| 31 | Kramer, Kelly A | Direct | Sell | 12012025 | 127.10 | 2,805 | 356,516 | 170,187 | Form | |
| 32 | O'Day, Daniel Patrick | Chairman & CEO | Direct | Sell | 12012025 | 126.54 | 10,000 | 1,265,444 | 72,282,528 | Form |
| 33 | Kramer, Kelly A | Direct | Sell | 12012025 | 127.11 | 2,806 | 356,671 | 170,200 | Form | |
| 34 | Dickinson, Andrew D | Chief Financial Officer | Direct | Sell | 11182025 | 125.23 | 2,500 | 313,075 | 19,354,923 | Form |
| 35 | Mercier, Johanna | Chief Commercial Officer | Direct | Sell | 11182025 | 125.86 | 28,000 | 3,524,173 | 13,491,669 | Form |
| 36 | Telman, Deborah H | EVP, Corporate Affairs & GC | Direct | Sell | 11132025 | 122.85 | 53,646 | 6,590,487 | 5,365,659 | Form |
| 37 | O'Day, Daniel Patrick | Chairman & CEO | Direct | Sell | 10292025 | 119.39 | 10,000 | 1,193,926 | 69,391,318 | Form |
| 38 | Dickinson, Andrew D | Chief Financial Officer | Direct | Sell | 10162025 | 118.08 | 2,500 | 295,200 | 18,545,054 | Form |
| 39 | Mercier, Johanna | Chief Commercial Officer | Direct | Sell | 10162025 | 118.08 | 3,000 | 354,240 | 13,011,589 | Form |
| 40 | O'Day, Daniel Patrick | Chairman & CEO | Direct | Sell | 9302025 | 111.66 | 10,000 | 1,116,564 | 66,011,598 | Form |
| 41 | Mercier, Johanna | Chief Commercial Officer | Direct | Sell | 9162025 | 113.57 | 3,000 | 340,710 | 12,855,329 | Form |
| 42 | Dickinson, Andrew D | Chief Financial Officer | Direct | Sell | 9162025 | 113.57 | 2,500 | 283,925 | 18,120,661 | Form |
| 43 | O'Day, Daniel Patrick | Chairman & CEO | Direct | Sell | 8292025 | 113.63 | 10,000 | 1,136,300 | 67,692,232 | Form |
| 44 | Mercier, Johanna | Chief Commercial Officer | Direct | Sell | 8182025 | 118.53 | 28,000 | 3,318,927 | 13,532,687 | Form |
| 45 | Dickinson, Andrew D | Chief Financial Officer | Direct | Sell | 8182025 | 118.53 | 2,500 | 296,325 | 18,977,838 | Form |
Investor Activity (13F)
Updated Aug 20, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Catalio Capital Management, LP | $22.8 Mil | 4.8% | 41 | TRIM -43.3% | 13F |
| Kiltearn Partners LLP | $14.0 Mil | 3.8% | 25 | TRIM -17.2% | 13F |
| ADAPT Investment Managers SA | $8.8 Mil | 3.0% | 34 | New | 13F |
| Atle Fund Management AB | $7.2 Mil | 2.3% | 39 | TRIM -5.6% | 13F |
| Sector Gamma AS | $7.4 Mil | 1.8% | 42 | TRIM -69.8% | 13F |
| Sprucegrove Investment Management LTD | $5.3 Mil | 0.8% | 42 | TRIM -36.7% | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Sector Gamma AS | $7.4 Mil | 1.8% | 42 | TRIM -69.8% | 13F |
| Catalio Capital Management, LP | $22.8 Mil | 4.8% | 41 | TRIM -43.3% | 13F |
| Sprucegrove Investment Management LTD | $5.3 Mil | 0.8% | 42 | TRIM -36.7% | 13F |
| Kiltearn Partners LLP | $14.0 Mil | 3.8% | 25 | TRIM -17.2% | 13F |
| Atle Fund Management AB | $7.2 Mil | 2.3% | 39 | TRIM -5.6% | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Catalio Capital Management, LP | $22.8 Mil | 4.8% | 41 | TRIM -43.3% | 13F |
| Kiltearn Partners LLP | $14.0 Mil | 3.8% | 25 | TRIM -17.2% | 13F |
| ADAPT Investment Managers SA | $8.8 Mil | 3.0% | 34 | New | 13F |
| Sector Gamma AS | $7.4 Mil | 1.8% | 42 | TRIM -69.8% | 13F |
| Atle Fund Management AB | $7.2 Mil | 2.3% | 39 | TRIM -5.6% | 13F |
| Sprucegrove Investment Management LTD | $5.3 Mil | 0.8% | 42 | TRIM -36.7% | 13F |
Gilead Sciences — Investor Video Playlist
Investor / Analyst
Gilead Sciences Q2 FY26 Earnings Call | $GILD | 🔴 WATCH LIVE
Investor / Analyst
GILD Stock: Margins Hit 78% — Q4 2025 Earnings Analysis
Investor / Analyst
Gilead Sciences Q4 2025 Earnings Call
Investor / Analyst
Gilead Q3 2025 Earnings: Strong Beats but Mixed Signals Explained
Investor / Analyst
Gilead Sciences, Inc GILD Q3 2025 Earnings Call
Leadership
Gilead: Working with external innovation communities_Silicon Valley Asian Business Talk_Stacey_Ma
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 8/19/2026